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Abstract. 
 
By using an immunoisolation procedure 
(Stan, R.-V., W.G. Roberts, K. Ihida, D. Predescu, L. 
Saucan, L. Ghitescu, and G.E. Palade. 1997. 
 
Mol. Biol. 
Cell.
 
 8:595–605) developed in our laboratory, we have 
isolated a caveolar subfraction from rat lung endothe-
lium and we have partially characterized the proteins of 
this subfraction which include an apparently caveolae-
speciﬁc glycoprotein we propose to call PV-1 (formerly 
known as gp68). The isolation and partial sequencing of 
PV-1, combined with the cloning of the full length 
 
PV-1
 
 
cDNA led to the following conclusions: (a) PV-1 is a 
novel single span type II integral membrane protein 
(438 amino acids long) which forms homodimers in situ; 
 
(b) the transmembrane domain of PV-1 is near the NH
 
2
 
 
terminus deﬁning a short cytoplasmic endodomain and 
a large COOH-terminal ectodomain exposed to the 
blood plasma; (c) PV-1 is N-glycosylated and its glycan 
antennae bear terminal nonreducing galactosyl resi-
dues in 
 
a
 
1-3 linkage. PV-1 is expressed mostly in the 
lung but both the messenger RNA and the protein can 
be detected at lower levels also in kidney, spleen, liver, 
heart, muscle, and brain. No signal could be detected in 
testis and two lower molecular weight forms were de-
tected in brain. Immunocytochemical studies carried 
out by immunodiffusion on rat lung with an anti–PV-1 
polyclonal antibody directed against a COOH-terminal 
epitope reveal a speciﬁc localization of PV-1 to the sto-
matal diaphragms of rat lung endothelial caveolae and 
conﬁrm the extracellular orientation of the PV-1 
COOH terminus.
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P
 
LASMALEMMAL
 
 vesicles (PVs)
 
1
 
 were first described
in endothelial cells (23) as spherical vesicles of reg-
ular size (
 
z
 
70 nm) and shape associated with the
plasma membrane (2). Similar structures were found in
epithelial cells and called caveolae intracellulares (39).
Subsequent studies have demonstrated the presence of ca-
veolae at different surface densities in practically all types
of mammalian cells with few exceptions (5, 11, 21).
Attempts to define the function of PVs have relied on
several approaches: (a) perfusion experiments with a vari-
ety of tracers carried on microvascular beds provided with
a continuous endothelium (9, 20, 27, 29, 30, 35) have estab-
lished the role of PVs in transcytosis but have not pro-
vided information about their chemistry; (b) immunocy-
tochemical tests carried on in situ have shown that certain
antigens are either restricted in their distribution to PVs
and absent or present at much lower density on the plas-
malemma proper (6, 8) or only partially present in PVs (7,
13–15, 22); and (c) attempts to isolate caveolae by cell
fractionation procedures from different cell types (3, 18,
19, 32, 36) including endothelial cells (33, 34). These cell
fractionation procedures employ nonspecific physical pa-
rameters (Triton X-100 insolubility, size, buoyant density)
of the caveolae and their membrane for their isolation and
purification. The results obtained by this approach consti-
tute already a sizable literature that ascribes to PVs a wide
variety of components and, by implication, functions (for
review see reference 1).
We have developed a caveolae purification procedure
(37) that uses as starting preparation luminal plasmalem-
mal patches isolated from rat lung vasculature by the cat-
ionized silica procedure (16), detaches the vesicles by soni-
cation, and isolates them by specific immunoabsorption on
magnetic microspheres coated with anticaveolin antibody.
 
Part of this work was submitted in abstract form to the 38th American So-
ciety for Cell Biology annual meeting, December 12–16, San Francisco
(
 
Mol. Biol. Cell. 
 
9[Suppl.].96a).
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Abbreviations used in this paper:
 
 aa, amino acid; GS I, 
 
Griffonia simplic-
ifolia
 
 I lectin; PBSA, 1% BSA in PBS; PEG, polyethylene glycol; PLP,
paraformaldehyde-lysine-metaperiodate fixate; PV, plasmalemmal vesi-
cles; PVDF, polyvinyldifluoride; RT, room temperature. 
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The procedure relies on the fact that caveolin is a gener-
ally accepted marker for caveolae (17, 25, 31). Our method
also has the advantage of permitting the comparison of the
protein and lipid content of immunoisolated caveolae with
that of a fraction derived primarily from the plasmalemma
proper. The results obtained with this immunoisolation
procedure are different from those obtained with proce-
dures that rely on physical parameters for caveolae purifi-
cation. For instance, proteins involved in signal transduc-
tion (c-src, endothelial nitric oxide synthase, annexin II,
protein kinase C
 
a
 
, 
 
a
 
 subunits of heterotrimeric G pro-
teins, 
 
a
 
s, 
 
a
 
i 1, 2, 3, and 
 
a
 
q) and novel endothelial specific
antigens, namely gp85/95 and gp95/115 (10), distribute
preferentially to the plasmalemma proper in our proce-
dure but are found enriched in caveolar fractions isolated
by other methods. Our results agree with previous immu-
nocytochemical findings on the distribution of several
endothelial antigens such as thrombomodulin, functional
thrombin receptor, podocalyxin (13, 14), or were later con-
firmed by immunolocalization studies in what concerns
the 
 
a
 
 subunits of the heterotrimeric G proteins (15) and
one novel endothelial antigen, namely gp85/95 (10).
The only protein found so far to strictly colocalize with
caveolin on the immunoisolated lung endothelial caveolae
is PV-1 (formerly known as gp68) (37). Accordingly, this
protein qualifies for a novel caveolar marker in rat lung
endothelium. PV-1 was discovered recently (10) as the an-
tigen recognized by a novel endothelial-specific mono-
clonal antibody (21D5 mAb). Partial characterization of
the PV-1 molecule, carried on in the same study, revealed
that: (a) PV-1 is an integral membrane protein (resistance
to extraction by high pH and high salt); (b) PV-1 forms
dimers (the 21D5 mAb recognizes a band at 
 
z
 
60–70 kD
apparent molecular mass in reducing conditions and a
band 
 
z
 
110–120 kD in nonreducing conditions); (c) PV-1
has an extracellular domain demonstrated by the possibil-
ity of biotinylation by perfusion in situ; (d) PV-1 is heavily
N-glycosylated (15% mass reduction after PNGase F
treatment); (e) PV-1 was detected in rat lung capillaries
and rat kidney peritubular capillaries by immunofluores-
cence; and (f) attempts to localize this protein to caveolae
isolated from rat lung endothelium by the Triton X-100
based purification procedure of Schnitzer et al. (33) have
failed as the protein is Triton X-100 soluble (10).
Since PV-1 strict colocalization with caveolin in lung en-
dothelial caveolae (obtained by immunoisolation on anti-
caveolin antibodies) may be functionally significant, we
decided to isolate it, obtain sequence information, and
identify it. As the peptide sequences we initially obtained
pointed to a completely novel protein, we cloned the full
length cDNA of PV-1 and localized its mRNA in different
rat tissues. We raised antibodies against a COOH-terminal
peptide of the translated sequence and detected it in dif-
ferent rat tissues by Western blotting and localized it by
immunocytochemistry at EM level in the rat lung.
 
Materials and Methods
 
Frozen rat lungs were purchased from Pel-Freez Biologicals. Ampholines
pI 3–10 and DEAE-Sephacel were from Pharmacia. Agarose bound or bio-
tinylated 
 
Griffonia simplicifolia
 
 I lectin (GS I) and melibiose were from
 
either Vector Laboratories or EY Laboratories. PVDF (polyvinyldifluo-
ride) membrane was purchased from Millipore and nitrocellulose mem-
brane from MSI. Protogel (30% acrylamide solution) was obtained from
National Diagnostics. The rat lung expression library and the rat multiple
tissue Northern Blot™ was purchased from Clontech. Protran 82 nitrocel-
lulose circles were purchased from Schleicher & Schuell. Bacto-Tryptone
and Bacto-Agar were from Difco and ampicillin, agarose, and Trizol™
from Life Technologies. Restriction enzymes were from New England
Biolabs and cloning vectors pBluescript SK (
 
2
 
) and pBluescript II KS
(
 
1
 
), 
 
pfu
 
 DNA polymerase, and QuickHyb™ hybridization solution were
from Stratagene. pCR 2.1 vector and TACloning™ kit were from Invitro-
gen Corp. pQE-30 cloning vector and QIAprep™ plasmid DNA miniprep
kits were from Qiagen. Luria-Bertani broth (LB-broth) and Luria-Bertani
agar (LB-agar) were purchased from Bio101. MaxiScript™ and RPA II™
kits were purchased from Ambion. [
 
32
 
P]dUTP and BSA were from ICN
Biomedicals. Hybond-N
 
1
 
 nylon membrane and [
 
32
 
P]dCTP were from
Amersham. All other reagents were either from Sigma Chemical Co. or
Fischer.
 
Buffers
 
Buffers were as follows: Hepes-buffered sucrose: 250 mM sucrose, 20 mM
Hepes, pH 7.2, supplemented with 5 mM MgCl
 
2
 
 and protease inhibitors
cocktail (10 
 
m
 
g/ml each leupeptin, pepstatin, 
 
o
 
-phenantrolin, E-64, and 1 mM
PMSF); Hepes-buffered saline (HBS): 150 mM NaCl in 10 mM Hepes, pH
7.2; Hepes-buffered saline/Triton X-100 (HBS-T): 0.2% Triton X-100,
150 mM NaCl in 10 mM Hepes, pH 7.2; lectin binding buffer: 0.2% Triton
X-100, 150 mM NaCl in 10 mM Hepes, pH 7.2, supplemented with 1 mM
each of CaCl
 
2
 
, MgCl
 
2
 
, and MnCl
 
2
 
.
 
PV-1 Isolation Procedure
 
Fig. 1 a gives the schematic of the PV-1 isolation procedure. Frozen rat
lungs were weighed, minced on ice in Hepes-buffered sucrose (1:4 wt/vol),
and homogenized in a motor driven Thomas type “C” Teflon pestle-glass
homogenizer by 15 strokes at 1,800 rpm. The homogenate was filtered
through a 53-
 
m
 
m nylon mesh and separated into a nuclear pellet and a
postnuclear supernatant by centrifugation (10 min, 1,800 
 
g
 
, 4
 
8
 
C) in a
Beckman GPR centrifuge. The postnuclear supernatant was resolved into
a total membrane pellet and a soluble supernatant by centrifugation (2 h,
100,000 
 
g
 
, 4
 
8
 
C) in a SW28 rotor. Next, the rat lung total membrane pellet
was resuspended in 25 ml of ice-cold 0.1 M Na
 
2
 
CO
 
3
 
, pH 11, by low speed
homogenization using a Thomas type “B” homogenizer followed by incu-
bation (15 min, 4
 
8
 
C) with gentle agitation. The insoluble material was col-
lected by centrifugation (1 h, 45,000 rpm, 4
 
8
 
C) in a Ti70 rotor and the su-
pernatant discarded. The pellet was further resuspended by gentle
homogenization in 20 ml ice-cold 2% Triton X-100 in 5 mM Hepes, pH
7.2, supplemented with protease inhibitors followed by a 1-h incubation at
4
 
8
 
C with end-over-end rotation. The Triton X-100 extract was clarified by
centrifugation (1 h, 45,000 rpm, 4
 
8
 
C) in a Ti70 rotor. The supernatant,
containing the Triton X-100 soluble proteins, was further adjusted to 4%
(wt/vol) urea, 2% (vol/vol) ampholines, pI 3–10, 1% (vol/vol) Triton
X-114, and 5% (wt/vol) glycerol to a final volume of 35 ml and subjected
to isoelectric focusing using a Rotofor chamber (Bio-Rad) as per manu-
facturer’s instructions. 20 fractions of 
 
z
 
1.7 ml were collected, subjected to
8% SDS-PAGE, and analyzed for the presence of PV-1 by Western blot-
ting using the anti–PV-1 21D5 mAb and by silver staining for visualization
of the protein content. The fractions containing the antigen (usually frac-
tions 11–14 counting from the acidic end of the gradient 
 
2
 
pH 3) were
pooled and dialyzed (4 h, 4
 
8
 
C) against 4,000 volumes of HBS-T using a
50-kD cut-off dialysis membrane. The dialysate was diluted 10
 
3
 
 with
HBS-T and next adjusted to 1 mM each CaCl
 
2
 
, MgCl
 
2
 
, and MnCl
 
2
 
. The re-
sulting mixture was incubated (10–12 h, 4
 
8
 
C) with 2 ml (settled gel) of GS
I-agarose with gentle rotation (GS I lectin specificity: Gal/GalNAc
 
a
 
1,3
[12].). The beads were collected by centrifugation (10 min, 500 
 
g
 
, 4
 
8
 
C) and
washed 3 
 
3
 
 10 min with 45 ml lectin binding buffer. GS I bound proteins
were eluted twice by incubation with 2.5 ml elution buffer (HBS-T supple-
mented with 0.2 M melibiose and 5 mM EDTA) for 1 h and the two elu-
ates pooled. The eluted glycoproteins were further incubated with 2 ml
(settled gel) DEAE-Sephacel (previously equilibrated with HBS-T) for 4 h
at 4
 
8
 
C. The flow-through was collected and subjected to 15% TCA precip-
itation for 1 h on ice. The precipitated proteins, representing the purified
material, were solubilized in 2
 
3
 
 reducing sample buffer, resolved by 8%
SDS-PAGE, and transferred to either PVDF (for NH
 
2
 
-terminal sequenc-
ing) or nitrocellulose (for internal sequencing) membrane. 
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NH
 
2
 
-terminal Sequencing
 
The PVDF membrane containing SDS-PAGE resolved proteins was
stained with 0.1% Coomassie brilliant blue G 250 in 40% methanol and
10% acetic acid and the PV-1 band was excised and used for Edman deg-
radation. The NH
 
2
 
-terminal sequencing was done on samples obtained
from two separate experiments by the protein sequencing facility at the
University of California, San Diego.
 
Internal Sequencing
 
The SDS-PAGE resolved proteins transferred to nitrocellulose mem-
brane were stained with 0.1% Ponceau S in 1% acetic acid and the PV-1
band was excised and digested with trypsin. Two of the resulting peptides
were purified, sequenced, and the sequence confirmed by mass spectrom-
etry by the protein sequencing laboratory at the Worcester Foundation
for Biomedical Research (Shrewsbury, MA).
 
Cloning of the Full Length PV-1 cDNA
 
We used the anti–PV-1 21D5 mAb to screen a rat lung expression library
(Clontech catalog No. RL5002b) cloned into the bacteriophage 
 
l
 
gt11
 
 as
per manufacturer’s instructions. Briefly, 500,000 phages were plated and
induced with 10 mM IPTG (isopropyl 
 
b
 
-
 
D
 
-thiogalactopyranoside) to ex-
press the proteins encoded by their inserts. The proteins were transferred
to nitrocellulose membranes which were probed by Western blotting with
the anti–PV-1 21D5 mAb. The positive plaques were purified to homoge-
neity by three more screening rounds. The four longest inserts were either
subcloned into pBluescript SK(
 
2
 
) vector or PCR amplified using 
 
l
 
gt11-
 
specific primers (sense: 5
 
9
 
TCCTGGAGCCCGTCAGTATCGGCG3
 
9
 
 and
antisense: 5
 
9
 
ATGGTAGCGACCGGCGCTCAGCTG3
 
9
 
) and the PCR
product inserted into pCR 2.1 vector. The resulting clones were se-
quenced in both directions which led to a partial sequence of 
 
PV-1
 
 mes-
sage. To obtain the full length cDNA we designed a 428-bp DNA probe
(residues 841–1268 in the rat 
 
PV-1
 
 full length cDNA) in the 5
 
9
 
 region of
the message obtained by screening with the antibody. This probe was 
 
32
 
P-
labeled using PrimeIt™ kit (Stratagene) and used to screen another
500,000 phages. 24 positive phage clones were purified to homogeneity
and the 5 longest inserts were sequenced after subcloning them into
pBluescript II KS (
 
1
 
) vector. The sequencing of these later inserts yielded
the full length 
 
PV-1
 
 message. DNA sequencing was performed on an ABI
Prism Sequencer (model 373XL) by either the Core Facility for AIDS Re-
search at the University of California, San Diego or the Sequencing Facil-
ity at the Scripps Research Institute (La Jolla, CA). The resulting se-
quences were analyzed using the MacVector release 6.0 software from
Oxford Molecular Group, Inc.
 
Northern Blots
 
A premade rat multiple tissue Northern blot containing 2 
 
m
 
g mRNA/lane
from different rat tissues was probed with a 
 
32
 
P-labeled 428-bp 
 
PV-1
 
cDNA fragment (residues 841–1268) for detection of the 
 
PV-1
 
 message.
The hybridizations were done using QuickHyb™ hybridization solution as
per manufacturer’s instructions.
 
RNase Protection Assay
 
A 283-bp fragment containing the nucleotides 1–283 of the full length 
 
PV-1
 
cDNA was PCR amplified, and the PCR product was gel purified and in-
serted into pCR 2.1 vector using the TACloning™ kit. The cloned insert
was checked by DNA sequencing and a 
 
32
 
P-labeled complementary RNA
probe was synthesized with T7 RNA polymerase using the MaxiScript™
kit. Total RNA from rat lung, spleen, kidney, and liver were purified using
the Trizol™ reagent as per manufacturer’s instructions. 20 
 
m
 
g of total
RNA from the above tissues was used in an RNase protection assay car-
ried out using RPA II™ kit and following the manufacturer’s standard
protocol. The reactions were resolved by 5% denaturing polyacrylamide
gel electrophoresis and the gel exposed to autoradiography film for 6–24 h.
 
Expression of PV-1 as a His-tagged Protein
 
The 
 
PV-1
 
 cDNA (residues 36–1797) was directionally subcloned in the
Figure 1. PV-1 isolation. (a)
Schematic of the isolation pro-
cedure of PV-1 from rat lung.
(b–g) Immunoblotting with
anti–PV-1 21D5 mAb of equiva-
lent volumes of fractions from
different steps in the isolation
procedure. (b) Rat lung homo-
genate separation into cytosol
and total membranes. Rat plasma
proteins (20 mg) were resolved
on the same gel to demonstrate
the blood plasma origin of the
lower (z45–50 kD) band recog-
nized by the 21D5 mAb in the
cytosolic fraction; (c) high-pH
soluble and insoluble material
resulted from extraction of rat
lung total membranes with 0.1 M
Na2CO3, pH 11; (d) Triton
X-100 soluble and insoluble ma-
terial resulted from the extrac-
tion of high-pH insoluble mate-
rial in 2% Triton X-100; and (e)
fractions resulted from the IEF
separation of the Triton X-100 extract in a Rotofor cell. (f) Equivalent amounts of fractions resulted from GS I chromatography of the
PV-1–containing Rotofor fractions (fractions 11–14 from e). (g) DEAE chromatography of the glycoproteins eluted from GS I column
(see Materials and Methods). To monitor PV-1 losses on the DEAE column, the column was washed with 10 ml HBS-T followed by 10
ml of HBS-T adjusted to 0.5 M NaCl final concentration. The proteins of the two washes were collected by TCA precipitation and solu-
bilized in 0.5 ml 23 reducing SDS-PAGE sample buffer. Equivalent volumes of the flow-through (FT), 0.15 M NaCl, and 0.5 M NaCl
wash were resolved by 8% SDS-PAGE and immunoblotted with the anti–PV-1 21D5 mAb. (h) Silver staining of the 8% SDS-PAGE
resolved proteins unbound to the DEAE-Sephacel column. The position of the reduced PV-1 is indicated by the arrow. 
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NcoI and PstI sites of the pQE-30 vector and the construct used to trans-
form competent 
 
Escherichia coli
 
 (M15 strain). Positive clones were cul-
tured for 6 h at 37
 
8
 
C until the OD
 
600
 
 
 
<
 
 0.7 and the recombinant protein
production was induced by the addition of IPTG to 1 mM final concentra-
tion. Aliquots of noninduced (control) and induced were collected by cen-
trifugation at 10,000 
 
g
 
 and solubilized in reducing SDS-PAGE sample
buffer. The solubilized bacterial proteins were resolved by 10% SDS-
PAGE, transferred to PVDF membrane, and immunoblotted using the
21D5 mAb.
 
Anti–PV-1C Polyclonal Antibody Production and
IgY Purification
 
A 14 mer peptide (KGPPLVNPAVPPSG single letter amino acid [aa]
code) corresponding to the 12 last COOH-terminal amino acids of rat PV-1
(to which a lysine and a glycine were added to facilitate the coupling and
to improve solubility) was synthesized by SynPep Corp. The peptide was
coupled to BSA via glutaraldehyde and this conjugate was used as antigen
for polyclonal antibody production in chickens at Lampire Biologicals us-
ing the company’s standard immunization protocol.
Total chicken IgY was purified from eggs laid by the immunized chick-
ens using a modified procedure of Polson et al. (26). Briefly, egg yolks de-
void of the amniotic sack were diluted 4
 
3
 
 in PBS and brought to 3.5%
polyethylene glycol (PEG). The precipitated lipoproteins were centri-
fuged for 25 min at 5,000 
 
g
 
 in a JA-14 rotor and the supernatant was saved.
The pellet was redissolved in 2
 
3
 
 initial yolk volume of PBS and a second
round of 3.5% PEG precipitation was performed as before. The two su-
pernatants were pooled, filtered through four layers of cheesecloth, and
centrifuged for an additional 30 min at 7,500 
 
g.
 
 The supernatant was fil-
tered through Whatman No. 4 filter paper, its volume measured (Z ml)
and mixed with 0.085 
 
3
 
 Z grams of PEG to precipitate IgY. The precipi-
tate was collected by centrifugation at 5,000 
 
g
 
 for 25 min. The pellet was
solubilized in PBS (2.5
 
3
 
 initial yolk volume) and IgY was again precipi-
tated using 3.5% PEG. The precipitate was collected by 5,000 
 
g
 
 centrifu-
gation for 25 min and redissolved in PBS (0.25
 
3
 
 initial yolk volume). This
IgY solution was chilled on ice for 10 min and mixed with an equal volume
of 50% ethanol which had been chilled at 
 
2
 
20
 
8
 
C. The precipitated IgY
was collected by 30 min of centrifugation at 10,000 
 
g
 
, redissolved in PBS
(0.25
 
3
 
 initial yolk volume), and dialyzed overnight against 20–40 vol of
PBS to yield a total IgY fraction from egg yolk.
 
Affinity Purification of Anti–PV-1C
Polyclonal Antibodies
 
The PV-1 COOH-terminal peptide used for immunizations (PV-1C pep-
tide) was solubilized in 0.1 M Hepes, pH 8.0, at a final concentration of 20
mg/ml and coupled to AffiGel-10™ beads (4 ml settled gel) (Bio-Rad) by
incubation (16 h, 4
 
8
 
C) with gentle agitation. After quenching (1 h, room
temperature [RT]) the remnant active sites with 0.2 M ethanolamine, pH
8.2, the matrix was packed into a column and washed with 100 bed vol of
PBS. Total IgY fraction from egg yolk was incubated (12–14 h, 4
 
8
 
C) with
the column with the help of a peristaltic pump. The column was washed
with 100 bed vol of PBS and the bound antibodies were eluted with 10 bed
vol of 0.1 M glycine, pH 2.5. Fractions of 1.4 ml were collected onto 100 
 
m
 
l
of 1.5 M Tris, pH 8.8, and promptly mixed for antibody activity preserva-
tion. Each fraction was monitored for protein content by absorbance at
280 nm and for antibody specific activity by ELISA assays using PV-1C
peptide–coated microwell plates. The fractions containing the antibody
were pooled, concentrated, and dialyzed at 4
 
8
 
C against 2 changes (4 h
each) of 100 vol of PBS using a 100 kD cut-off dialysis membrane.
 
Anti–PV-1C Polyclonal Antibody Validation
 
ELISA. 
 
Affinity purified anti–PV-1C pAb was checked for specificity and
activity in an ELISA assay using serial dilutions of the antibody on 10 ng
PV-1C peptide/plate well. The bound anti–PV-1C antibody was detected
using an anti–chicken IgY HRP-conjugated reporter antibody (Biodesign)
and TMB (3, 3
 
9
 
, 5, 5
 
9
 
 tetramethylbenzidine) substrate (KPL) for colori-
metric reaction. Either preimmune IgY or an irrelevant peptide was used
as negative controls.
 
Immunoblotting and Peptide Competition. 
 
Whole rat lung lysate pro-
teins (200 
 
m
 
g) were resolved by preparative 10% SDS-PAGE and trans-
ferred to a PVDF membrane which was subsequently blocked (30 min,
RT) in 5% nonfat dry milk in PBS and 0.1% Tween 20. Strips, containing
 
z
 
20 
 
m
 
g protein, were cut and incubated (1 h, RT) with either serial dilu-
 
tions of the anti–PV-1C pAb or 21D5 mAb or preimmune IgY (as positive
and negative controls, respectively). The bound antibody was detected by
incubation (30 min, RT) with a rabbit anti–chicken IgY HRP-conjugated
antibody (Biodesign) and enhanced chemiluminescence (Super Signal™;
Pierce). In the case of the peptide competition, 1-
 
m
 
g aliquots of anti–PV-1C
pAb were incubated (1 h, RT) with different amounts of the peptide prior
to the incubation with the strips.
 
Immunoprecipitations. 
 
Rat lung membranes were extracted for 1 h on
ice in immunoprecipitation buffer (20 mM Tris-HCl, pH 7.5, containing
1% NP-40, 0.4% deoxycholate, 0.1% SDS, 300 mM NaCl, 1 mM EDTA,
1 mM PMSF, and protease inhibitor cocktail). The extract was clarified by
centrifugation at 100,000 
 
g for 1 h in a TLA45 rotor. The extracted pro-
teins (200 mg) were incubated (14 h, 48C) with 5 mg of anti–PV-1C pAb
with gentle agitation. This mixture was further incubated (4 h, 48C) with
anti–chicken IgY antibodies insolubilized onto agarose beads to precipi-
tate the antigen-antibody complexes. The beads were collected by centrif-
ugation (500 g, 5 min) and washed (3 3 5 min) with immunoprecipitation
buffer followed by one final wash in 50 mM Tris, pH 6.8. The beads were
boiled in nonreducing SDS-PAGE sample buffer (2.3% SDS, 10% glyc-
erol, 62.5 mM Tris-HCl, pH 6.8) and collected by centrifugation. The su-
pernatant containing the solubilized antigen-antibody complexes was
saved, adjusted to 5% 2-mercaptoethanol, and boiled again for 2 min. The
solubilized proteins were resolved by 8% SDS-PAGE, transferred to
PVDF membrane, and immunoblotted using the anti–PV-1 21D5 mAb.
For visualization of the immunoprecipitated protein, the solubilized anti-
gen-antibody complexes were resolved in nonreducing conditions on 12%
SDS-PAGE and silver stained. Control experiments were carried out by
replacing the anti–PV-1C pAb with preimmune total IgY or by omitting it.
Western Blotting of Different Rat Tissues. Total membranes from dif-
ferent rat organs or tissues were prepared as in the case of the lung and
high-pH extracted. The high-pH insoluble material (containing PV-1) was
extracted in 0.5% SDS in 50 mM Tris, pH 6.8, and protease inhibitor cock-
tail, clarified by centrifugation for 30 min at 12,000 g, and the protein
content determined. Equal amounts of protein (300 mg) from different
rat tissues and 10 mg in the case of the lung were separated by 8% SDS-
PAGE, transferred to PVDF, and immunoblotted using the anti–PV-1
21D5 mAb.
Electron Microscopy
Preembedding Immunocytochemistry. Preembedding immunocytochemis-
try was performed as previously described in Predescu et al. (28). Briefly,
the tissue was flushed free of blood by a 10-min perfusion with Hank’s bal-
anced salt solution, then fixed in situ by a 30-min perfusion of paraformal-
dehyde-lysine-sodium metaperiodate (PLP) fixative. The tissue was ex-
cised, cut into small blocks (z3 3 3 mm), further fixed in fresh PLP for 1 h
at RT, and then fixed overnight at 48C (with a fresh PLP change). Fixed
specimens were cryoprotected by infiltration (12–16 h at 48C followed by
1 h at RT) with a solution containing 1.5 M sucrose, 50% polyvinylpyroli-
done in PBS, and stored frozen in liquid nitrogen. Thick cryostat sections
(z45 mm) cut from the fixed blocks were rinsed (5 3 5 min) and incubated
overnight at 48C in 10% goat serum in PBS, quenched in 1% BSA in PBS
(PBSA) for 30 min at RT and incubated overnight at 48C with the anti–
PV-1C pAb diluted (1:50–1:250) in PBSA. The sections were washed 3 3
30 min in PBSA at RT, incubated with the rabbit anti–chicken IgY 5 nm
gold-conjugated antibody (1:100 dilution in PBSA) for 12–16 h at 48C. Af-
ter final washes as above the antibody-antigen complexes were stabilized
by fixation (1 h at RT) in 2% glutaraldehyde in 0.1 M cacodylate buffer,
pH 7.3, postfixed in 1% OsO4 in acetate veronal buffer, pH 6.8 (1 h on
ice), stained in the dark (1 h at RT) with Kellenberger uranyl acetate, de-
hydrated through graded ethanols, and finally embedded in Epon 812
resin. Tissue blocks were cured for 48 h at 908C, and z50-nm sections, cut
on a Reichert microtome, mounted on formvar-coated nickel grids, and
stained with 2% uranyl acetate and saturated lead citrate. The stained sec-
tions were examined and photographed in a Philips CM10 electron micro-
scope.
This approach for immunolabeling relying on the diffusion of the anti-
bodies along vascular and perivascular spaces provides adequate sampling
of morphologically well preserved vascular endothelia.
Postembedding Immunogold. Small blocks (1 3 1 mm) from PLP fixed
lungs, cryopreserved and stored as above, were sectioned on a Reichert
ultramicrotome equipped with a F4 cryoattachment. Ultrathin cryosec-
tions transferred to nickel grids were stained and then washed by floating
the grids, specimen down, on drops of filtered solutions (41). After
quenching (30 min at RT) with 1% BSA and 0.01 M glycine in PBS, theStan et al. Rat PV-1 1193
sections were incubated (1 h, RT) with anti–PV-1C pAb diluted 1:100 in
PBSA, washed (3 3 15 min) in PBSA, and further incubated with a rabbit
anti–chicken IgY antibody conjugated to 5 nm colloidal gold (diluted
1:100 in PBSA) for 2 h at RT, then washed as above. The immune com-
plexes were stabilized (30 min at RT) in 2% glutaraldehyde in PBS, post-
fixed in 1% OsO4 in acetate-veronal buffer, pH 7.6, absorption-stained (5
min, RT) with 0.002% lead citrate in 2.2% polyvinylalcohol, and finally
examined and photographed in a Philips CM10 electron microscope. This
procedure has the disadvantage of a limited yield of useful sections and
suboptimal structural preservation, but the advantage of providing infor-
mation on the intracellular distribution of the antigen.
General Procedures
Protein Determination. The protein content was determined by the BCA
method (Pierce) against either BSA or IgY standards made in appropriate
buffers.
Immunoblotting. The membranes were blocked (30 min, RT) in 5%
nonfat dry milk in PBS and 0.1% Tween 20 (blocking buffer), incubated
(1 h, RT) with the first antibody diluted in blocking buffer, washed (3 3 5
min) in PBS containing 0.1% Tween 20, incubated (30 min, RT) with a
HRP-conjugated reporter antibody, washed again as above, and the signal
detected by using ECL reagents.
Results
Isolation of PV-1 from Rat Lungs
As the monoclonal antibody 21D5 is not a useful reagent
for affinity purification of PV-1, we explored alternative
approaches taking advantage of the already known prop-
erties of this protein (molecular weight, occurrence as a
dimer, and resistance to high-pH and high-salt extraction).
Pilot experiments as Triton X-100 differential solubility, pI
determination, lectin binding and elution, and anion ex-
change chromatography were carried out using rat lung to-
tal membranes to assess the behavior of PV-1 in any of the
isolation steps.
Based on the pilot experiments, the isolation of PV-1
from rat lungs was carried out according to the protocol
depicted in Fig. 1 a and detailed in Materials and Methods.
Aliquots of different fractions throughout the purification
procedure were monitored for presence of PV-1 by immu-
noblotting using the 21D5 mAb.
The frozen rat lungs were minced, homogenized, and re-
solved by centrifugation in a tissue debris and nuclei pellet
and a postnuclear supernatant. The latter was used for ob-
taining a total membrane fraction containing PV-1. As
documented in Fig. 1 b, PV-1 distributes exclusively in the
total membrane fraction. However, the anti–PV-1 21D5
mAb recognizes another band of z45–50,000 molecular
weight which we determined to be a soluble rat blood
plasma protein (see Fig. 1 b, rat plasma and rat lung cyto-
sol lanes) which is efficiently eliminated by the centrifuga-
tion step used to separate membranes from cytosol. To
eliminate the membrane associated proteins, the rat lung
total membranes were high-pH extracted, the insoluble
material which contained PV-1 (Fig. 1 c) collected by cen-
trifugation, and the supernatant discarded. This high-pH
insoluble material was further extracted in 2% Triton
X-100 and the extract clarified by centrifugation. Fig. 1 d
shows the efficiency of PV-1 extraction which was essen-
tially complete. The clarified Triton X-100 extract was fur-
ther subjected to isoelectric focusing in a Rotofor cham-
ber. PV-1 was recovered in 3–4 fractions of the pI gradient
(fractions 11–14 in Fig. 1 e) corresponding to a pI interval
6.85–7.9. These fractions were pooled, dialyzed, and in-
cubated with GS I lectin bound to agarose. After wash-
ing nonspecifically interacting proteins the bound glyco-
proteins were eluted by competition with melibiose and
EDTA (Fig. 1 f). GS I lectin was chosen for the isolation
procedure for two reasons. First, the binding efficiency
and especially elution efficiency were the highest com-
pared to other lectins tested (our unpublished data); and
second, the binding sites for this lectin have been docu-
mented at the electronmicroscopic level in rat lung by pre-
vious work done in our laboratory (2). This study has
shown some of the binding sites of GS I to be located in
the caveolae of the rat lung endothelium and endothelia of
other microvascular beds. The eluate from GS I column
was further subjected to DEAE-Sephacel chromatogra-
phy and the flow-through was collected, as PV-1 binds
very weakly (Fig. 1 g) to this anion exchange column. We
introduced this step because DEAE binds proteins in the
50–70 kD range, thereby improving the separation of PV-1
from other bands and making possible its excision free of
contaminants. The proteins from the flow-through were
precipitated by TCA, solubilized in 23 reducing sample
buffer, and resolved by 8% SDS-PAGE to obtain maxi-
mum resolution in the 50–60,000 molecular weight range
(Fig. 1 h). The resolved proteins were transferred to either
a PVDF or a nitrocellulose membrane, the PV-1 band
identified, excised, and sent for NH2-terminal or internal
sequencing. The sequences of three peptides, one repre-
senting the NH2 terminus of PV-1 (NH2-terminal) and the
other two representing internal sequences (Internal 1 and
Internal 2) were obtained (Table I). Mass spectrometry
analysis was carried out on the internal peptides for confir-
mation of the sequence. Searches of protein databases and
mass spectrometry databases showed that these sequences
are novel, as very little homology with other known pro-
teins was found.
PV-1 Cloning from a Rat Lung Library
The anti–PV-1 21D5 mAb was used for screening an oligo-
dT and random primed rat lung expression library cloned
in the bacteriophage lgt11 and the inserts of the positive
phages were sequenced as described in Materials and
Methods. Only 1,274 nucleotides of the PV-1 full length
message were obtained by this approach. Additionally, we
were able to narrow down the region where the epitope of
the 21D5 mAb is located as the overlap of the cloned
phage inserts amounted to a sequence of 39 nucleotides
(residues 1240–1278 of the PV-1 full length cDNA) which
encodes for the amino acid residues 405–417 of the PV-1
translated protein sequence (Fig. 2 c). To obtain the se-
quence of the full length message, the same library was re-
screened with a 32P-labeled DNA probe (residues 841–
Table I. Peptide Sequences Obtained by
PV-1 Microsequencing
Sequence Position Full length PV-1 residues
MGLSMDRSPYSRTGDR NH2-terminal 1–16
FQADVLNVWR Internal 1 231–240
SLDNIGYHYSLMPEFSS Internal 2 247–264The Journal of Cell Biology, Volume 145, 1999 1194
1268 of PV-1 full length cDNA). Upon sequencing of
seven longest inserts isolated through the second screen-
ing we obtained an 1968-nucleotide message (Fig. 2 a).
The size of the message was confirmed by Northern blot-
ting of mRNA from different rat tissues using the same
DNA probe that had been used for screening of the library
(Fig. 3).
Along with the full length PV-1 cDNA we found one al-
ternatively spliced form lacking the region in between res-
idues 116–252. An RNase protection assay (see Materials
and Methods) with a probe appropriate for D116–252 form
showed that .99% of the naturally occurring message
consisted of the full length RNA in rat lung, kidney,
spleen, and liver (our unpublished results).
The longest region of the full length PV-1 cDNA which
encodes for protein is 1,341 bases long and contains all
three peptides obtained by protein sequencing of the puri-
fied PV-1 (Fig. 2 a). Even though there is no stop codon
before the initiator ATG and the consensus Kozak se-
quence is incomplete (G is present in the position 14 but
no A or G is found in position 23) we set the beginning of
the coding region at residue 25 of the PV-1 full length
cDNA based on the sequence obtained by NH2-terminal
sequencing of the purified PV-1 (Table I).
The full length PV-1 cDNA encodes for a protein with a
calculated 50 kD mass and an estimated pI z9.0. Hydro-
philicity plot (Fig. 2 b) shows only one hydrophobic region
(aa residues 25–50) which could qualify for a transmem-
brane domain. As no signal peptide could be found, the
hydrophobic region (aa residues 25–50) could act as a sig-
nal and anchoring peptide thus defining PV-1 as a type II
membrane protein with its NH2 terminus intracellular and
COOH terminus extracellular. Searches of protein data-
bases with the translated protein sequence show little ho-
mology with known proteins. No known long protein pat-
terns and few protein motifs were detected. Noteworthy
features of PV-1 are the four consensus N-glycosylation
sites (arginines 82, 88, 112, and 150), an odd number (nine)
of cysteines in the extracellular domain which would imply
the possibility of intermolecular disulfide bonds, a short
proline-rich region (residues 397–411) at the COOH ter-
minus, and two casein kinase consensus phosphorylation
Figure 2. (a) Sequence of the
full length rat PV-1 cDNA and
protein. The positions of the
peptides obtained by protein mi-
crosequencing (square boxes)
and the putative transmembrane
domain (oval box) are indicated.
The portion of the PV-1 message
that was obtained by rescreening
of the rat lung library with a
DNA probe (see Materials and
Methods) is underlined. These
sequence data are available from
GenBank/EMBL/DDBJ under
accession number AF154831. (b)
Hydrophilicity plot and (c) sche-
matic of the protein sequence.
The positions of the consensus
phosphorylation sites (*), N-gly-
cosylation sites (Y), cysteines ( ),
the 21D5 mAb epitope (filled
box), and the proline-rich region
(PRR) are marked. The number
of amino acids in between cys-
teines is indicated.Stan et al. Rat PV-1 1195
sites (the serine 4 [SMD] and threonine 13 [TGD]) in the
cytoplasmatic domain. No consensus O-glycosylation sites
were found. A striking feature of PV-1 is the regular pat-
tern formed by the spacing of the cysteines in the extracel-
lular domain starting with the cysteine in position 117
(C-23X-C-10X-C-24X-C-20X-C-24X-C-44X-C-67X-C-38X),
whose significance, if any, is not known. A schematic of
PV-1 monomer and the representation of different fea-
tures is given in Fig. 2 c.
To prove that this cDNA encodes indeed for PV-1, we
expressed recombinant PV-1 as a His-tagged protein in
bacteria (see Materials and Methods). The 21D5 mAb de-
tected by immunoblotting a single band at z50 kD (the
size of the unglycosylated PV-1 monomer) only in the in-
duced transformant bacterial clones but not in the nonin-
duced (our unpublished results).
Detection of the PV-1 mRNA by Northern Blotting
The presence of the PV-1 mRNA in several rat tissues was
checked by Northern blotting (see Materials and Meth-
ods). As PV-1 was implied to be an endothelial antigen
(10) we screened tissues containing several endothelial
types (e.g., continuous, fenestrated, and sinusoidal). We
found the PV-1 message to be present mostly in the lung
and at much lower levels in kidney, spleen, liver, heart,
and muscle (in decreasing order of the signal intensity)
(Fig. 3). A very weak signal, if any, of the PV-1 full length
mRNA along with very low levels of two shorter mRNA
species was found in the brain only after long exposure of
the blot to the film (Fig. 3, lane B). No message was de-
tected in testis.
Anti–PV-1 Polyclonal Antibody Production
Since we found that the 21D5 mAb was not a useful re-
agent for immunoprecipitation or immunolocalization of
PV-1 at the EM level (our unpublished results) we raised
polyclonal antibodies in chickens against a 12 mer COOH-
terminal peptide representing residues 427–438 of rat PV-1
to which a lysine and a glycine were added for coupling
purposes (PV-1C peptide). The peptide (KGPPLVN-
PAVPPSG single letter amino acid code) was coupled to
BSA via glutaraldehyde and the resulting conjugate was
used as antigen for antibody production in chickens.
A total yolk IgY fraction was purified and used for anti–
PV-1C pAb affinity purification as described in Materials
and Methods.
The chicken anti–PV-1C pAb was checked in immuno-
blotting on PVDF strips containing 10% SDS-PAGE re-
solved rat lung total membranes proteins. As seen in Fig. 4
a the anti–PV-1C antibody recognizes with high specificity
a band of the same molecular weight as the one seen by
the 21D5 mAb when reacted with the same material. The
specificity of the binding is confirmed by competition with
the peptide antigen (Fig. 4 c). Moreover, the anti–PV-1C
Figure 3. Northern blotting
of rat tissues. Rat lung total
RNA (20 mg) was probed
with a 428-bp 32P-labeled
PV-1 DNA fragment as de-
scribed in Materials and
Methods. A single band cor-
responding to the PV-1
mRNA was obtained at
z2000 nt in heart (H), spleen (S), lung (L), liver (Li), muscle
(M), and kidney (K). No message was obtained in the testis (Te).
Exposure time: upper panel, 4 h; lower panel, 12 h.
Figure 4. Anti–PV-1C chicken polyclonal antibody specificity.
(a) Immunoblotting of rat lung total membrane proteins contain-
ing strips with 1 mg of each 21D5 mAb, preimmune IgY, and
anti–PV-1C polyclonal antibody as indicated in the figure. (b)
Immunoblotting of rat blood plasma (Pl), rat lung cytosol (C),
and rat lung membranes (M) (10 mg each) in nonreducing (left)
and reducing (right) conditions. (c) Competition of the anti–PV-
1C pAb by the PV-1C peptide compared with an irrelevant (ca-
veolin) peptide. (d) Immunoprecipitation of rat PV-1 using the
anti–PV-1 C pAb followed by immunoblotting of equivalent
amounts of the immunoprecipitated (IP) and the unbound (NB)
material using the 21D5 mAb. (e) Immunoprecipitation of rat
lung PV-1 with anti–PV-1C pAb as described in Materials and
Methods. The immunoprecipitated proteins by anti–PV-1C pAb
(lane 1), preimmune total IgY control (lane 2), and anti–chicken
IgY-agarose control (lane 3) were resolved by 12% SDS-PAGE
in nonreducing conditions and silver stained. The asterisk marks
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pAb is highly specific for PV-1; by immunoblotting it de-
tects a single band of either z110,000 or z60,000 apparent
molecular weight in nonreducing or reducing conditions,
respectively, and does not detect any protein in either rat
plasma or rat lung cytosol (Fig. 4 b). By immunoprecipita-
tion, the chicken anti–PV-1C pAb binds a protein which is
recognized by the 21D5 mAb by immunoblotting on the
immunoprecipitated material (Fig. 4 d). Silver staining of
the immunoprecipitated material detects a single band of
z120,000 (Fig. 4 e, lane 1) apparent molecular weight in
nonreducing conditions.
Taken together, these data show that the new chicken
anti–PV-1C pAb recognizes PV-1 with high specificity in
immunoblotting and immunoprecipitation thus being an
appropriate reagent for attempts to localize PV-1 in the
rat lung by immunocytochemistry techniques.
Localization of PV-1 by Western Blotting
The anti–PV-1C pAb was used in an immunoblotting as-
say to check for the presence of PV-1 in different rat tis-
sues (see Materials and Methods and Fig. 5 legend). When
equal amounts of protein from different rat tissue total
membranes were loaded, the antibody detected the pro-
tein only in the lung in the linear part of the film, and in
the lung and faintly in the spleen and kidney when the
exposure time was highly increased. When the protein
amount ratio of lung to other tissues was 1:30 (Fig. 5) the
signal was easily detected in spleen, kidney, and liver,
thereby matching the data obtained by Northern blotting.
No signal was detected in brain, testis, heart, and muscle.
Immunolocalization of PV-1 in the Rat Lung
Rat lung specimens processed and labeled as described in
Materials and Methods were examined by transmission
electron microscopy.
In the case of preembedding immunocytochemistry,
which documents the distribution of PV-1 on the cellular
surface, the gold particles were found primarily on the en-
dothelial plasmalemmal vesicles (caveolae) in agreement
with the results previously obtained by the immunoisola-
tion procedure of endothelial caveolae (37). Interestingly,
the label was found mostly associated with the neck of the
caveolae or their stomatal diaphragms at both fronts of the
endothelial cells, although the frequency of the label was
considerably higher on the luminal side presumably re-
flecting higher accessibility from the lumen (Fig. 6, a–e). In
oblique or en face views, the diaphragms occasionally ap-
peared labeled by a cluster of gold particles (Fig. 6 d).
Very little label, if any, was found on the endothelial plas-
malemma proper, coated pits, or other cellular types to
which the label had access in our lung preparations (e.g.,
epithelial cells lining alveoli and other airways structures).
This finding is taken to indicate the specificity of PV-1 lo-
calization to endothelial caveolae. Control experiments in
which the anti–PV-1 antibody was either omitted or re-
placed with an irrelevant antibody or preimmune IgY con-
firmed the specificity of the localization. Moreover, the
immunocytochemical findings reinforced the conclusion
that PV-1 is a type II membrane protein with the COOH
terminus accessible from the microvascular lumina.
By immunogold labeling of ultrathin (z60 nm) rat lung
cryosections the label was found at comparable frequen-
cies on the caveolae at both fronts of the endothelial cell
as well as vesicles within the cytoplasm (our unpublished
results), pointing to the fact that PV-1 is a caveolar resi-
dent protein.
Discussion
The present study takes advantage of: (a) the specific pro-
cedure we (37) devised for the purification of caveolae
from rat lung endothelium by immunoisolation on antica-
veolin antibody–coated magnetic beads; and also (b) the
availability of a novel monoclonal antibody (21D5 mAb)
(10) directed against a rat lung endothelial antigen (PV-1).
We found that this antigen colocalizes strictly with caveo-
lin on immunoisolated caveolae, thus qualifying for a
novel caveolar marker in rat lung endothelium. In light of
this fact we decided to isolate this protein in order to ob-
tain sequence information for its identification and further
characterization.
The PV-1 isolation method presented in this study em-
ploys several of its already documented properties: PV-1 is
an integral membrane protein resistant to extraction by
high salt and high pH, that forms dimers, is N-glyco-
sylated, and is Triton X-100 soluble. Novel findings are the
slightly alkaline pI of the dimer and the presence of ter-
minal, nonreduced galactosyl residues in a1-3 linkage
(proven by the binding to GS I lectin) on PV-1 glycan an-
tennae. Even though the isolation method yields several
protein bands at its final step, as judged by the silver stain-
ing of SDS-PAGE resolved proteins from the purified ma-
terial, it permits a sufficient separation of PV-1 band from
other peptides to be useful for band excision and protein
sequencing. As the NH2-terminal and internal sequences
obtained from the PV-1 protein band pointed to a novel
protein, we went further for cloning of the PV-1 full length
cDNA from a rat lung expression library.
The deduced protein sequence encoded by PV-1 full
length cDNA contains all three peptides obtained by pro-
tein sequencing. Further confirmation that this cDNA en-
codes for PV-1 came from the expression of PV-1 as a His-
tagged protein in E. coli and the detection of an z50,000
apparent molecular weight band (which would represent
the nonglycosylated form of PV-1 monomer) by the 21D5
mAb only in the transformed bacterial clones.
Analysis of the primary structure of the PV-1 confirms
its already known properties such as dimer formation,
membrane insertion, and glycosylation. Additional infor-
mation is represented by the possibility of phosphoryla-
tion of the cytoplasmic domain, which might be involved
Figure 5. Western blotting of
different rat tissues using the
anti–PV-1C pAb. Proteins
from total membranes from
different rat tissues were prepared as in Materials and Methods
and immunoblotted with the anti–PV-1C pAb (1:500 dilution)
followed by an HRP-conjugated anti–chicken IgY reporter anti-
body and the signal was detected by enhanced chemilumines-
cence. B, brain; H, heart; M, muscle; K, kidney; Li, liver; Lu,
lung; S, spleen; Te, testis.Stan et al. Rat PV-1 1197
in the regulation of the protein, and the presence of the pu-
tative protein-protein interaction motif (38) represented
by the proline-rich region at the COOH terminus.
Sequence analysis of the PV-1 cDNA and the deduced
protein sequence shows that PV-1 is a novel protein, as lit-
tle homology with other known proteins was found by
searches of DNA and protein databases. This is a notable
finding when correlated with the results obtained by im-
munocytochemistry at EM level which demonstrate the
strict localization of PV-1 to endothelial caveolae in rat
lung: (a) it brings further proof for the special chemistry of
the caveolar microdomains (in addition to lipids and cave-
olins); and (b) it provides another marker for caveolae in
rat lung endothelium useful in further studies of these sub-
cellular structures. Moreover, PV-1 strict localization to
caveolae in the rat lung endothelium brings additional val-
idation to the procedure of caveolae purification by spe-
cific immunoisolation as the results obtained by the two
approaches are in agreement. By immunoisolation the la-
bel colocalizes strictly with caveolin on immunoisolated
caveolae (37). We assume that the protein is anchored in
the membrane and is incorporated within the caveolae
upon detachment by sonication. We recognize, however,
that by immunocytochemistry the label is found mostly on
the necks and the stomatal diaphragms as well as in the
vesicles. PV-1 is a single span type II transmembrane pro-
tein and its extracellular domain is z390 aa long, which
would amount to z100 nm long if fully extended. Consid-
ering the inner diameter of endothelial caveolae of z40–
50 nm (average), it might be that the protein is anchored at
the level of the caveolar membrane and either: (a) partici-
pates in the formation of the diaphragms; or (b) its COOH
terminus protrudes through the stomatal diaphragm. The
participation of PV-1 in the structure of the diaphragms is
further sustained by the possibility of protein-protein in-
teraction via the proline-rich region at the COOH ter-
minus.
We have named PV-1 in light of its localization in caveo-
lae in endothelium of rat lung. However, the data by
Northern and Western blotting indicate that the messen-
ger and the gene product is present in other organs which
contain endothelia in part fenestrated and in part provided
with caveolae. The association of PV-1 with the stomatal
diaphragms of caveolae in the lung endothelium, and the
findings that PV-1 is present in tissues where endothelial
caveolae are known to have stomatal diaphragms (4, 24,
and references therein) are consistent with a strict caveo-
lar localization. If PV-1 is associated only with the endo-
thelial caveolae in these tissues it might be that this pro-
tein has a function in the transport of macromolecules into
or across the endothelium. If PV-1 is also associated with
other structures (e.g., diaphragms of the transendothelial
channels and fenestrae) in these endothelia, its distribu-
tion would suggest a sieving function for this protein. The
latter hypothesis would be the most interesting as PV-1
would be the first protein of this type to perform such a
Figure 6. Immunolocaliza-
tion of PV-1 in rat lung by
preembedding immunocy-
tochemistry. Rat lung speci-
mens prepared as described
in Materials and Methods
were reacted with anti–PV-
1C pAb followed by a 5 nm
gold-conjugated reporter an-
tibody. The label (arrow-
heads) was found associated
specifically with the necks
and stomatal diaphragms of
endothelial caveolae (a–e) at
both fronts of the endothelial
cell (a, b, and e). Most caveo-
lar stomatal diaphragms are
marked by a single gold par-
ticle and occasionally by a
cluster of particles (a, d, and
e). No label was found on ei-
ther plasmalemma proper
(a–e) or coated pits (cp in d).
Bars, 100 nm.The Journal of Cell Biology, Volume 145, 1999 1198
function. Continuation of this work will find out if PV-1 is
restricted only to caveolae in these “mixed” microvascular
beds. Precise information on the localization of PV-1 in
different microvascular beds is a prerequisite for the for-
mulation of any hypothesis as to its function.
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